



Figure S1. Evidence network with regard to (A) overall mortality, (B) mortality due to rebleeding, (C) mortality due to liver failure, (D) treatment failure and (E) bleeding from gastroesophageal ulcer.


A Overall mortality




B Mortality due to rebleeding



C Mortality due to liver failure



D Treatment failure



E Bleeding from gastroesophageal ulcer




Table SI. Risk of bias assessment in included randomized controlled trials.

First author (year)	Concealment of randomization	Early trial cessation ^a	Participants blinded	Health care providers blinded	Data collectors blinded	Outcome assessors blinded	(Refs.)
Sauerbruch (2015)	Yes	No	No	No	No	No	(20)
Luo (2015)	Yes	No	N.A.	N.A.	N.A.	N.A.	(21)
Kumar (2015)	Yes	No	N.A.	N.A.	N.A.	N.A.	(22)
Kumar (2009)	Yes	No	No	No	No	No	(24)
Sauer (2002)	Yes	No	N.A.	N.A.	N.A.	N.A.	(25)
Gülberg (2002)	Yes	No	N.A.	N.A.	N.A.	N.A.	(26)
Escorsell (2002)	Yes	No	N.A.	N.A.	N.A.	N.A.	(27)
Villanueva (2001)	Yes	No	N.A.	N.A.	N.A.	N.A.	(28)
Pomier-Layrargues (2001)	Yes	No	N.A.	N.A.	N.A.	N.A.	(29)
Narahara (2001)	Yes	No	N.A.	N.A.	N.A.	N.A.	(30)
Sauer (1997)	Yes	No	N.A.	N.A.	N.A.	N.A.	(24)
Villanueva (1996)	Yes	No	N.A.	N.A.	N.A.	N.A.	(26)
Holster (2016)	Yes	No	N.A.	N.A.	N.A.	Yes	(38)
Ahmad (2009)	Yes	No	N.A.	N.A.	N.A.	N.A.	(44)
Argonz (2000)	Yes	No	N.A.	N.A.	N.A.	N.A.	(44)
Avgerinos (1997)	Yes	No	No	No	No	No	(45)
Avgerinos (2002)	Yes	No	N.A.	N.A.	N.A.	N.A.	(47)
Chen (2016)	Yes	No	Yes	No	N.A.	Yes	(16)
García-Pagán (2009)	Yes	No	N.A.	N.A.	N.A.	N.A.	(50)
de la Peña (2005)	Yes	Yes ^b	No	No	No	No	(55)
de la Peña (1999)	Yes	No	N.A.	N.A.	N.A.	N.A.	(56)
Romero (2006)	Yes	No	Yes	Yes	Yes	Yes	(57)
Stiegmann (1992)	Yes	No	N.A.	N.A.	N.A.	N.A.	(58)
Umeshara (1999)	Yes	No	N.A.	N.A.	N.A.	N.A.	(59)
Viazis (2002)	Yes	No	N.A.	N.A.	N.A.	N.A.	(60)
Vinel (1992)	Yes	No	N.A.	N.A.	N.A.	N.A.	(61)

^aOnly trials that declared early cessation or premature termination were considered to feature 'Early trial cessation'. ^bThe author declared early trial cessation for ethical reasons, as relevant statistical differences between the two treatment groups were identified in the interim analysis. N.A., no information provided.